Allied Biotech Profit Margin

The latest profit margin for 1780.TWO is 13.28% as of June 2026. That compares with 16.58% in the prior-year period — down 19.9% year over year. That is above the sector sector average of 13.16%. Investors often review this figure alongside Allied Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 1780.TWO's profit margin moved from 16.58% to 13.28% — a 19.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Allied Biotech's valuation or profitability profile.

Against its sector companies, 1780.TWO currently prints 13.28% for profit margin, while the sector average sits near 13.16%. That is roughly 0.9% above the sector mean. Large gaps often invite a closer look at Allied Biotech's growth, margins, and balance sheet.

Profit Margin shows how effectively Allied Biotech converts resources into returns. At 13.28%, 1780.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 16.58% in the prior-year period — down 19.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 1780.TWO's profit margin (13.28%), review year-over-year change from 16.58%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.